Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers
  16. CDN Services

We are analyzing https://www.nature.com/articles/s41586-021-03392-8.

Title:
The changing landscape of atherosclerosis | Nature
Description:
Emerging evidence has spurred a considerable evolution of concepts relating to atherosclerosis, and has called into question many previous notions. Here I review this evidence, and discuss its implications for understanding of atherosclerosis. The risk of developing atherosclerosis is no longer concentrated in Western countries, and it is instead involved in the majority of deaths worldwide. Atherosclerosis now affects younger people, and more women and individuals from a diverse range of ethnic backgrounds, than was formerly the case. The risk factor profile has shifted as levels of low-density lipoprotein (LDL) cholesterol, blood pressure and smoking have decreased. Recent research has challenged the protective effects of high-density lipoprotein, and now focuses on triglyceride-rich lipoproteins in addition to low-density lipoprotein as causal in atherosclerosis. Non-traditional drivers of atherosclerosis—such as disturbed sleep, physical inactivity, the microbiome, air pollution and environmental stress—have also gained attention. Inflammatory pathways and leukocytes link traditional and emerging risk factors alike to the altered behaviour of arterial wall cells. Probing the pathogenesis of atherosclerosis has highlighted the role of the bone marrow: somatic mutations in stem cells can cause clonal haematopoiesis, which represents a previously unrecognized but common and potent age-related contributor to the risk of developing cardiovascular disease. Characterizations of the mechanisms that underpin thrombotic complications of atherosclerosis have evolved beyond the ‘vulnerable plaque’ concept. These advances in our understanding of the biology of atherosclerosis have opened avenues to therapeutic interventions that promise to improve the prevention and treatment of now-ubiquitous atherosclerotic diseases. This Review discusses recent research that has transformed our understanding of the biology of atherosclerosis, and examines its implications for the treatment of atherosclerotic cardiovascular disease.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,058 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$63,100 per month
Estimations show Nature.com's display ad online revenue falls between $42,042 and $115,617 per month.

Keywords {🔍}

pubmed, article, google, scholar, cas, central, atherosclerosis, cardiovascular, disease, med, risk, nature, engl, libby, coronary, cardiol, heart, res, coll, circulation, inflammation, outcomes, circ, cells, atherosclerotic, clinical, review, ldl, cholesterol, study, nat, acute, artery, access, cell, rev, patients, vascular, data, lowdensity, clonal, plaque, eur, myocardial, infarction, ads, diabetes, endothelial, content, evidence,

Topics {✒️}

permissions reprints nature portfolio journals genome editing nature portfolio interest policies scientific advisory boards received research funding privacy policy advertising high-sensitivity c-reactive protein author information authors social media recent research atherosclerosis research elevated c-reactive protein regional haemodynamic stress-induced breaches dynamic nature human atheroma-asociated cells single-cell transcriptome atlas subscribe nature author correspondence prospective natural-history study policy priorities nature+ nature 444 nature 558 nature 589 nature nature 569 nature 592 interferon-γ contributes low-density lipoprotein-reactive central nervous system potent age-related contributor innate immune memory national gender-specific trends circ-psmb1 knockdown inhibits aggregated low-density lipoproteins large-scale clinical trials paper presents data atherosclerosis auto-antigen targeted permissions unraveling anti-atherosclerosis mechanism rapid development randomised placebo-controlled trial synergistic anti-atherosclerosis therapy blood-cancer risk inferred springerlink instant access endothelial cell metabolism

Questions {❓}

  • Diabetic macrovascular disease: the glucose paradox?
  • Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?
  • How common is residual inflammatory risk?
  • Lipoprotein (a): a frustrating final frontier in lipid management?
  • Should we stay or should we go?
  • Triglycerides on the rise: should we swap seats on the seesaw?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The changing landscape of atherosclerosis
         description:Emerging evidence has spurred a considerable evolution of concepts relating to atherosclerosis, and has called into question many previous notions. Here I review this evidence, and discuss its implications for understanding of atherosclerosis. The risk of developing atherosclerosis is no longer concentrated in Western countries, and it is instead involved in the majority of deaths worldwide. Atherosclerosis now affects younger people, and more women and individuals from a diverse range of ethnic backgrounds, than was formerly the case. The risk factor profile has shifted as levels of low-density lipoprotein (LDL) cholesterol, blood pressure and smoking have decreased. Recent research has challenged the protective effects of high-density lipoprotein, and now focuses on triglyceride-rich lipoproteins in addition to low-density lipoprotein as causal in atherosclerosis. Non-traditional drivers of atherosclerosis—such as disturbed sleep, physical inactivity, the microbiome, air pollution and environmental stress—have also gained attention. Inflammatory pathways and leukocytes link traditional and emerging risk factors alike to the altered behaviour of arterial wall cells. Probing the pathogenesis of atherosclerosis has highlighted the role of the bone marrow: somatic mutations in stem cells can cause clonal haematopoiesis, which represents a previously unrecognized but common and potent age-related contributor to the risk of developing cardiovascular disease. Characterizations of the mechanisms that underpin thrombotic complications of atherosclerosis have evolved beyond the ‘vulnerable plaque’ concept. These advances in our understanding of the biology of atherosclerosis have opened avenues to therapeutic interventions that promise to improve the prevention and treatment of now-ubiquitous atherosclerotic diseases. This Review discusses recent research that has transformed our understanding of the biology of atherosclerosis, and examines its implications for the treatment of atherosclerotic cardiovascular disease.
         datePublished:2021-04-21T00:00:00Z
         dateModified:2021-04-21T00:00:00Z
         pageStart:524
         pageEnd:533
         sameAs:https://doi.org/10.1038/s41586-021-03392-8
         keywords:
            Atherosclerosis
            Dyslipidaemias
            Inflammation
            Science
            Humanities and Social Sciences
            multidisciplinary
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41586-021-03392-8/MediaObjects/41586_2021_3392_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41586-021-03392-8/MediaObjects/41586_2021_3392_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41586-021-03392-8/MediaObjects/41586_2021_3392_Fig3_HTML.png
         isPartOf:
            name:Nature
            issn:
               1476-4687
               0028-0836
            volumeNumber:592
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Peter Libby
               url:http://orcid.org/0000-0002-1502-502X
               affiliation:
                     name:Brigham and Women’s Hospital
                     address:
                        name:Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, USA
                        type:PostalAddress
                     type:Organization
                     name:Harvard Medical School
                     address:
                        name:Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The changing landscape of atherosclerosis
      description:Emerging evidence has spurred a considerable evolution of concepts relating to atherosclerosis, and has called into question many previous notions. Here I review this evidence, and discuss its implications for understanding of atherosclerosis. The risk of developing atherosclerosis is no longer concentrated in Western countries, and it is instead involved in the majority of deaths worldwide. Atherosclerosis now affects younger people, and more women and individuals from a diverse range of ethnic backgrounds, than was formerly the case. The risk factor profile has shifted as levels of low-density lipoprotein (LDL) cholesterol, blood pressure and smoking have decreased. Recent research has challenged the protective effects of high-density lipoprotein, and now focuses on triglyceride-rich lipoproteins in addition to low-density lipoprotein as causal in atherosclerosis. Non-traditional drivers of atherosclerosis—such as disturbed sleep, physical inactivity, the microbiome, air pollution and environmental stress—have also gained attention. Inflammatory pathways and leukocytes link traditional and emerging risk factors alike to the altered behaviour of arterial wall cells. Probing the pathogenesis of atherosclerosis has highlighted the role of the bone marrow: somatic mutations in stem cells can cause clonal haematopoiesis, which represents a previously unrecognized but common and potent age-related contributor to the risk of developing cardiovascular disease. Characterizations of the mechanisms that underpin thrombotic complications of atherosclerosis have evolved beyond the ‘vulnerable plaque’ concept. These advances in our understanding of the biology of atherosclerosis have opened avenues to therapeutic interventions that promise to improve the prevention and treatment of now-ubiquitous atherosclerotic diseases. This Review discusses recent research that has transformed our understanding of the biology of atherosclerosis, and examines its implications for the treatment of atherosclerotic cardiovascular disease.
      datePublished:2021-04-21T00:00:00Z
      dateModified:2021-04-21T00:00:00Z
      pageStart:524
      pageEnd:533
      sameAs:https://doi.org/10.1038/s41586-021-03392-8
      keywords:
         Atherosclerosis
         Dyslipidaemias
         Inflammation
         Science
         Humanities and Social Sciences
         multidisciplinary
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41586-021-03392-8/MediaObjects/41586_2021_3392_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41586-021-03392-8/MediaObjects/41586_2021_3392_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41586-021-03392-8/MediaObjects/41586_2021_3392_Fig3_HTML.png
      isPartOf:
         name:Nature
         issn:
            1476-4687
            0028-0836
         volumeNumber:592
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Peter Libby
            url:http://orcid.org/0000-0002-1502-502X
            affiliation:
                  name:Brigham and Women’s Hospital
                  address:
                     name:Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, USA
                     type:PostalAddress
                  type:Organization
                  name:Harvard Medical School
                  address:
                     name:Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature
      issn:
         1476-4687
         0028-0836
      volumeNumber:592
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Brigham and Women’s Hospital
      address:
         name:Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, USA
         type:PostalAddress
      name:Harvard Medical School
      address:
         name:Harvard Medical School, Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Peter Libby
      url:http://orcid.org/0000-0002-1502-502X
      affiliation:
            name:Brigham and Women’s Hospital
            address:
               name:Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, USA
               type:PostalAddress
            type:Organization
            name:Harvard Medical School
            address:
               name:Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, USA
      name:Harvard Medical School, Boston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(501)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {📦}

  • Crossref

4.44s.